| Chemical Properties | Back Directory | [Melting point ]
>250 °C (decomp) | [Boiling point ]
371.2±32.0 °C(Predicted) | [density ]
1.443±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
2.07±0.60(Predicted) |
| Hazard Information | Back Directory | [Description]
LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively[1].
mGluR2|0.161 μM (IC50)|mGluR3|1.05 μM (IC50)
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 15 min prior) induces a concentration-dependent inhibition of the TAP evoked fEPSPs in CA1-SLM in 10-16 week old (EC50 42 nM) in CD-1 mice[1]. LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 30 min prior) reduces the increased locomotor activity of phencyclidine and amphetamine in a dose-dependent manner in male ICR mice[1]. | [Uses]
LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively[1]. | [in vivo]
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 15 min prior) induces a concentration-dependent inhibition of the TAP evoked fEPSPs in CA1-SLM in 10-16 week old (EC50 42 nM) in CD-1 mice[1].
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 30 min prior) reduces the increased locomotor activity of phencyclidine and amphetamine in a dose-dependent manner in male ICR mice[1]. | [IC 50]
mGluR2: 0.161 μM (IC50); mGluR3: 1.05 μM (IC50) | [References]
[1]. Hanna L, et al. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist. Neuropharmacology. 2013 Mar;66:114-21. |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|